DE29623125U1 - Colostral milk products - Google Patents

Description

296 23 125.8 A 3829 - Cs/ho Charlotte Adler Michael Achenbach

Colostrum milk products

The present invention relates to colostrum milk products.

It has long been known that the colostrum - i.e. the first milk - of all mammals, including humans, contains valuable components that protect newborns from infections and have other beneficial effects.

For example, EP-AO 173 999 describes a process for the production of immunoglobulins from bovine or human colostrum, whereby an immunoglobulin fraction is obtained from bovine or human colostrum which is suitable both in human medicine and in veterinary medicine for the treatment or prophylaxis of bacterial and viral intestinal infections.
25

For example, it has been found that the co-

Lostralimmunobuiines were effective against the bacteria: Escherichia coli, Pseudomonas aeruginosa, Klebsiella, staphylococci, enterococci and streptococci and against the viruses: varicella virus, cytomegalovirus, rubella virus, herpes virus and rotavirus.

Such a colostral globulin fraction was produced by

Processing of colostrum by precipitation of caseins at a pH value of 4.0 to 5.5 and subsequent filtering of the cheese cake by tangential titration and subsequent ultrafiltration with a cut-off of 5,000 to 80,000 Dalton.'

Since the germ content in raw colostrum can be between 10^ and 10^ germs per milliliter, EP-A-0 471 890 deals with a process for obtaining sterile-filtered, casein-containing colostrum, in which the raw colostrum is acidified to such an extent that the casein that initially precipitates goes back into solution and the resulting solution is then sterile-filtered.

The teaching of EP-A-O 471 890 assumes that casein itself has beneficial therapeutic properties that particularly support the effect of immunoglobulins in gastrointestinal disorders. According to this state of the art, for example, opiate-like active substances are released from casein, which lead to the inhibition of intestinal movement and the promotion of electrolyte and water absorption. Therefore, according to the teaching of EP-A-O 471 890, it is desirable to change the protein composition of colostrum as little as possible, since it is composed almost optimally for the prophylaxis and treatment of gastrointestinal infections and disorders.

In addition, WO 95/10192 describes a nutritional drink based on colostrum, which improves physical performance and recovery.

Such a drink is produced by defatting the colostrum and then precipitating and filtering off the casein and sterile filtering the resulting colostrum liquid.

However, such a colostrum milk product has the disadvantage that, due to the casein precipitation, many beneficial components of the colostrum, such as the content of growth factors, for example IGF-1, IGF-2 or TGF-ß, are reduced and therefore the yield of such a colostrum milk product in relation to the raw colostrum is only poor, and sometimes certain growth factors such as IGF-2 and TGF-ß can no longer be detected at all.

Based on this state of the art, it was therefore the task of the present invention to create a largely decaseinated colostrum milk product 2ai, which in particular contains the growth factors contained in colostrum as quantitatively as possible.

The solution to this problem is specified in the claims.

By acidifying the casein so that it remains in solution and then carrying out ultrafiltration with a rejection molecular mass of approx. 10^ Daiton, the raw colostrum is freed of casein. This is particularly desirable for allergy sufferers and people with neurodermatitis, as casein can have undesirable side effects for these people. On the other hand, surprisingly, ultrafiltration achieves a content of up to approx. 95% of growth factors, especially IGF-1, based on the content of the raw colostrum.

It is particularly surprising that casein, with a molecular mass of approximately 150 10 ⁶ Daiton and its huge surface area, can be separated by ultrafiltration, whereby the desired low molecular weight components of the colostrum, such as growth factors and peptides, pass almost quantitatively into the filtrate - i.e. without being bound to the huge protein surface of the casein.

A colostrum product according to the invention is useful for many applications in the therapeutic and food supplement sector. For example, a study of high-performance athletes showed that the creatine kinase in the serum, an indicator of physical exertion, was significantly lower when the test subjects had taken the colostrum product according to the invention in solid or liquid form, either regularly over a longer period of time or immediately before heavy physical exertion.

■ *

Regarding this mechanism, it should be said - without being limited to this - that creatine kinase is always released by muscle cells when muscle cells are damaged in some way. Such damage occurs, for example, after extreme physical exertion, or in the case of pathological symptoms such as heart attacks or muscle diseases. Several studies have now shown, including a double-blind study during the Winter Olympics in Liliehammer with the Finnish ski team, that colostrum milk products reduce the concentration of free creatine kinase in the serum by 30 to 40 percent, which means that performance is maintained significantly longer and the regeneration time, i.e. the refractory stage of the muscles, is noticeably shortened.

Furthermore, it is known from in vitro studies that colostrum supports the viability and growth of various cell types in cell culture, as it essentially has four main fractions, namely:

a growth factor fraction, an immunoglobulin fraction, an enzyme protein fraction and a vitamin and peptide fraction.

■

It is also known from studies of colostrum that these essential components of colostrum essentially reach their peak at the birth of the calf and that just 6-12 hours after birth they have already lost more than half of their content of essential components and then steadily decrease over the next few days, with only traces remaining after 3-4 days.

It has also been shown that colostrum products can be given to athletes at sporting events without any problems, as they do not contain any doping substances.

In addition, it has been found that the inventive

Colostrum milk product as a medicinal product, food supplement or

Cosmetics and as an additive for medicinal products,

Food supplements, beverages or cosmetics can be used.

In addition to its use in sports and extreme sports, outstanding therapeutic successes have been achieved in the treatment of neurodermatitis. For this purpose, the colostrum milk product according to the invention was preferably enclosed in liposomes and mixed into a cream base and applied to the affected areas of skin of patients suffering from neurodermatitis.

In addition, the colostrum product according to the invention was administered in the form of a drink.

The patient collective included 20 adult people suffering from neurodermatitis who suffered from neurodermatitis symptoms, especially in the elbows. The patients did not take any medication, but treated the affected skin areas with a cream containing the colostrum milk product according to the invention. The concentration of the

Colostrum milk product in the cream was approximately 10% by weight. The cream base used was, for example, soybean oil, Tegomuls, vitamin E + A, cholesterol, HSA, Contrex, carotene DF + HF, orange blossom oil, lemon balm oil, mandarin oil, neroli oil, and distilled water. Alternatively, neurodermatitis can also be treated with a liposome cream whose liposomes contained the colostrum milk product according to the invention. The concentration of liposomes in the cream base (e.g. soybean oil, Tegomuls, vitamin E -f- A, cholesterol, HSA, Contrex, carotene DF + HF, orange blossom oil, lemon balm oil, mandarin oil, neroli oil, and distilled water) was approximately 0.1 ml/g or 10% liposomes.

The treatment was carried out for 14 days and then assessed by the treating doctor. It was found that 18 of

20 patients showed an almost 90 percent reduction in neurodermatitis skin symptoms. Both the liposome cream and the orally administered colostrum product drink were then discontinued for 14 days and the neurodermatitis exanthemas were again examined by a doctor. It then turned out that all patients with a predominant reduction in skin symptoms after the first colostrum product treatment period were now again suffering from significant neurodermatitis eczema.

A treatment period of 14 days was then scheduled again, during which the affected skin areas were again treated with the cream or liposome cream containing the colostrum milk product according to the invention enclosed in liposomes, and 10 ml per day of a colostrum milk product drink was administered as a supplement, and the skin symptoms were again examined by a doctor.

It turned out that 17 of 20 subjects who took part in the study showed a significant reduction in neurodermatitis eczema.

From this cross-over study it is clearly evident that the improvement of the neurodermatitis skin condition is due to the applied colostrum product according to the invention.
25

First studies over a longer period of about 6 months

also show that the colostrum milk product according to the invention, preferably in the form of a dermatological agent, in particular a cream, lotion or ointment, is suitable as a long-term therapeutic agent for the skin symptoms of neurodermatitis.

In addition, a control study with placebo lipo-

somen cream, whereby the cream base was the same as in the test group, but the liposomes only contained physiological saline solution. As an additional drink,

decaseinated milk instead of the coiostral whey according to the invention.

Within the control group of 15 subjects with neuroderma-

tic skin manifestations showed only two significant

Improvements in skin symptoms after a 14-day treatment interval.

This placebo-controlled experiment further confirms the effectiveness of the colostrum product according to the invention.

In addition to the already mentioned endurance-enhancing effect and the beneficial effect on the recovery phase of the muscles and the above-proven effect on neurodermatitis, the colostrum milk product according to the invention can also be used as a component of baby food, dietary food, clinical food, especially tube feeding, as well as for rheumatic diseases, allergies, especially hay fever, poultry allergies, heart attacks and muscular diseases during rehabilitation. These effects are particularly evident in the reduction of creatine kinase, which is an indication of a recovery phase of the muscles. It has also been found that the colostrum milk products according to the invention are suitable for supporting liver and bone disease therapies.

Furthermore, the colostrum product according to the invention also has a beneficial effect on the prophylaxis and support of viral, bacterial and mycotic infections and generally on the support and strengthening of the immune system, which is explained by the increased content of _{immunoglobulins,} in particular IgG, IgA, IgE and IgM. Furthermore, TGF-ß also plays a not insignificant role in the immune system, since TGF-ß acts on the ß-lymphocytes and causes a switch from IgE to IgA and has an effect on the immune response.

In addition, it has been found that the colostrum product according to the invention also has beneficial effects on wound healing.

■&igr; :"·:. r»v.:r;"

has, especially in post-operative care or minor injuries, with oral and additional local topical application.

The subclaims represent preferred embodiments of the present invention.

Further advantages and features are apparent from the description of examples of implementation,

example 1

20 liters of defatted bovine colostrum, obtained in the first 24 hours after the birth of the calf, were brought to a pH of 2.54 at + 4 ^° C by adding 60 mMol EDTA and then 365 ml HCl. This pH-reduced bovine colostrum was then ultrafiltered at an exclusion molecular weight of 1,000,000 Da, with the temperature being kept constant at + 4 ° C to + 8 ^° C. A Millipore 1000 KD filter module made of cellulose acetate was used because of its low protein binding. 10 L of permeate were obtained. The yield with this procedure was 50%. After ultrafiltration, the clear permeate was raised to a pH of 6.2 with 250 ml NaOH. The slight turbidity this resulted in was removed by centrifugation. The now clear permeate was diluted with 10 L of distilled water. diluted and subjected to a further ultrafiltration with a rejection molecular mass of 1000 Da in order to remove the salt produced by the pH reduction and subsequent pH increase. This also results in simultaneous desugaring. Again, the bovine colostrum product was kept at a constant temperature of + 4°C to + 8°C and ultrafiltered until the initial amount of 10 liters of retentate was reached. This retentate was sterile filtered using the conventional method at 0.22 μm. No prefilters had to be used. The product was easy to sterile filter. An analysis was then carried out.

The colostrum milk product obtained by the process according to the invention had the following analytically determined composition according to Table 1.

Particularly striking is the high proportion of immunoglobulins and growth factors, especially IGF-1.

Such a colostrum product can be used directly as a drink or can be added to various foods, for example baked goods, in particular energy bars, preferably so-called power bars. The addition to baked goods or bars is preferably carried out after spray drying or freeze drying.

Table 1 80.0 kJ/100g Energy content 6.16 pH 264.0 mOsm/kg Osmolarity 0.3 g/i Total protein 5.24 g/i Dry matter 0.68 mg/100ml ash 0.2 mg/100ml lactose 10.0 mg/100ml Glucose 20.0 g/i . Total carbohydrates <0.03 mg/100ml Fat VITAMINS <150.0 μg/100 ml Vitamin A 63.5 μg/100 ml Thiamine (VitBi) 620.0 μ§/100 ml Riboflavin (vitamin B2) 3500.0 μg/100 ml Pyridoxine (Vit. B6) 0.034 μg/10O ml Cobalamin (Vit. B12) 2.65 μg/100 ml Folic acid 270.0 ' >g/100-mr vitamin C

Cholecalciferol (Vit.D3) 0.28 μg/100 ml

Tocopherol (Vit. E) 30.0 μg/100 ml

Vitamin K 0.054 μ9/100 ml

Ubiquinone {Vit.Q 10) 5.4 μg/100 ml

IONS

Sodium (Na) Potassium (K) Calcium (Ca) Magnesium (Mg) Iron (Fe) Copper (Cu) Zinc (Zn) Chromium (Cr) Phosphorus (P) Selenium (Se)

943.7 mg/l 1883.5 mg/! 490.52 mg/l 147.98 mg/! -: 0.02 mg/! 0.004 mg/l 0.30 mg/l 0.0014 mg/l 498.0 mg/! 0.018 mg/!

&Ggr;&zgr;&zgr;-'tu &igr;

ORGANIC MOLECULES

Creatinine

17.2 mg/l

FREE AMINOSAURINES

Alanine 6.60 mg/l Arginine 0.0056 5 mg/ml Tryptophan 2.66 mg/l Cystine <0.27 mg/l Methionine ■- ¹ ' ⁰³ mg/! Phosphoserine 1.05 mg/l Ta urine <0.363 mg/l Phosphoethanoiamine 7.31 mg/l Aspartic acid 4.85 mg/l Threonine 0.0001 4 mg/l Serine 4.85 mg/l Glutamic acid 9.44 mg/l Glutamine 7.99 mg/l Proline ■ 7.37 mg/l Glycine 4.85 mg/l Alanine 6.6 mg/l Citrulline 1.05 mg/l Valine 11,13 mg/l isoleucine 4.85 mg/l Leucin 9.44 mg/l Tyronsine 3.26 mg/! Phenylalanine 4.95' mg/l ß-Alanine <0.27 mg/l ß-Aminoisobutyric acid 1.03 mg/l Ornithine 0.53 mg/l O/sin 7.99 mg/!

&Ggr;&ogr;· 09*97

IMMUNGLOBULINS

IgG 98.0 mg/100 ml

IgA 3.0 mg/100 ml

IgM 2.0 mg/100 ml

IgE 0.026 μg/100ml

NATURAL GROWTH FACTORS

IGF-1 (Somatomedin C) .380.0 ng/ml

IGF-2 242.0 ng/ml

TGF-ß 35.0 ng/ml

Example 2

The pH reduction, ultrafiltration, pH increase and centrifugation were carried out as in Example 1. Then, to increase the yield, 10 L of distilled water, which had also been brought to pH 2.54, were added. Ultrafiltration was continued and another 10 L of permeate was obtained. This permeate was ultrafiltered together with the permeate from the first ultrafiltration and an additional 10 liters of distilled water with a rejection molecular mass of 500 Da, using an ultrafiltration membrane from Amicon. Here too, the temperature was kept constant at + 4° C to + 8 ⁰ C. Ultrafiltration was continued until 15 L of retentate remained. This increased the yield to 75%. This retentate was sterile-filtered using the conventional method at 0.22 μπα. No pre-filters had to be used. The product was light and could be sterilized by filtration. An analysis was then carried out. The results are shown in Table 2.

Comparison example 1

20 L of defatted colostrum were slightly warmed (approx. 38 ^° C) and reduced to pH 4.5 with 240 ml of HCl. The casein clumped and was easily removed with a sieve and subsequent centrifugation. Clouding of the whey could not be prevented. The whey was then ultrafiltered with an exclusion molecular weight of 1,000,000 Da, using a module from Millipore. 7 L of permeate were obtained and brought to pH 6.2 with 80 ml of NaOH. A slight cloudiness again occurred, which could be removed by centrifugation. The permeate was sterile-filtered using the conventional method at 0.22 μπα. No prefilters had to be used. The product was easy to sterile-filter. An analysis was then carried out. The results are shown in Table 2.

Comparison game 2

20 L of defatted colostrum were slightly warmed (approx. 38°C) and lowered to pH 4.5 with 240 ml of HCl. The casein clumped and was easily removed with a sieve and subsequent centrifugation. The pH was then brought back to pH 6.2 with 100 ml of NaOH and ultrafiltered with an exclusion molecular mass of 1,000,000 Da using a module from Millipore. 7 L of permeate was obtained. This was then sterilized using the conventional method at 0.22 μm. No prefilters had to be used. The product was easily sterilizable. An analysis was then carried out. The results are shown in Table 2.

Comparison example 3

20 L of defatted colostrum were reduced to pH 4.5 at + 4°C to + 8 ⁰ C with 240 ml HCl. It was found that the casein did not clump sufficiently. No real whey could be obtained. The curdled casein was centrifuged off and the remaining milk was ultrafiltered with an exclusion molecular weight of 1,000,000 Da using a module from Miüipore. The resulting permeate (8.5 L) was brought to pH 6.3 with 100 ml NaOH and the turbidity was centrifuged off again. The permeate was then sterile-filtered using the conventional method at 0.22 μπα. No prefilters had to be used. The product was easy to sterile-filter. An analysis was then carried out. The results are shown in Table 2.
15

Comparison example 4

20 L of defatted colostrum were ultrafiltered directly without pretreatment at an exclusion molecular weight of 1,000,000 Da, using a module from Millipore. 10 L of permeate were obtained. This was then sterile filtered using the conventional method at 0.22 μl. No prefilters had to be used. The product was easily sterile filtered. An analysis was then carried out. The results are shown in Table 2.

In Example 2 and the comparative examples, only the 1GF-1 and TGF-ß concentrations and the immunoglobulin G were determined, which contained the following values:

Table 2

IGF-I
(ng/ml) ■ TGF-ß
(ng/ml) IgG
(mg/100ml) Example 2 371 30 87 Comparison
example 1 81 Sense 43 Comparison
example 2 48 not
verifiable 25 Comparison
example 3 63· not
verifiable 35 Comparison
example 4 23 not
verifiable 15

From these results it was clear that a pH reduction followed by ultrafiltration, without raising the pH again before ultrafiltration, produces better results than, for example, ultrafiltration without pH reduction. It was also shown that a pH reduction to approx. 4.5 also does not produce a satisfactory result, since not all proteins dissolve at pH 4.5 and many valuable proteins are carried away when the coagulated casein is removed. Temperature also plays an important role, since an increase in temperature makes ultrafiltration impossible as the colostrum thickens.

Only the procedures given in Examples 1 and 2 showed satisfactory results.

Comparison example 5

For further comparison with a product according to the present invention, the same starting quantities of raw colostrum as in Example 1 were used and defatted as described above, but the defatted raw colostrum was then adjusted to a pH value of approx. 4.5 and passed through a microfilter with a pore size of approx. 5

·|; ^: &ngr;&Pgr; ^! >97

separated. The resulting whey filtrate was then adjusted to a pH value of approx. 7 by adding sodium hydroxide and then sterile filtered.

The analysis of such a colostrum product according to the state of the art is shown in Table 3.

A comparison of the growth factor fraction shows an approximately 100% lower content of IGF-1 and unmeasurable values of iGF-2 and TGF-ß. The colostrum milk product according to the invention therefore has a significantly higher content of the growth factors required for the favorable pharmacological and vital effects and also has a significantly higher immunoglobulin content.

Comparison example 5 80.0 kJ/100g Table 3 6.55 Energy content 418.0 mOsm/kg pH 0.43 g/100ml Osmolarity 5.24 g/100ml Total protein 0.82 g/100ml Dry matter <0.5 g/100ml ash 1.91 g/100ml lactose 4.0 g/100 I Glucose <0.02 g/100ml Total carbohydrate 0.039 g/100ml Fat IgG VITAMINS

Thiamine (Vit. 81) Riboflavin (Vit. B2) Pyridoxine (Vit. B6) Cobalamin (Vit. B12)

40.0 μg/100 ml

180.0 μg/100 ml

T2.0 μg/100m!

0.04-1 -μηι/�IΩΩαια

1498.9 mg/l 1599.2 mg/l 280.15 mg/l 109.88 mg/! <0.22 mg/l <0.05 mg/! <0.05 mg/! <0.05 mg/l <0.01 mg/l 480.0 mg/l 0.002 mg/l

Folic acid 4.2 μg/100 ml

Nicotinamide 83.0 μg/ml

Pantothenic acid 300.0 μg/100 ml

/O/VflV

Sodium (Na) Potassium (K) Calcium (Ca) Magnesium (Mg) Iron (Fe) Copper (Cu) Manganese (Mn) Zinc (Zn) Chromium (Cr) Phosphorus (P) Selenium (Se)

ORGANIC MOLECULES

Creatinine 34.4 mg/l

Creatine 127.0 mg/!

FREE AMINO ACIDS

Arginine

Tryptophan Cystine

Methionine Phosphoserine Ta urine

Rhosphoethanolamine Aspartic acid Threonine Serine

Glutamic acid

5.6 mg/! <6.1 mg/l <0.7 mg/! 1.0 mg/! 9.06 mg/! 115.0 mg/l 27.37 mg/l 2.66 mg/l 3.1 mg/l 5.04 mg/! 37-,tD ■ mg/l

»· * * I &udigr; -51 Glutamine α · · · 7.31 mg/l &bull;·&diams; · · * ·'
₍ , · * · · ··· '
·«· ·· »· »· Proline * ·
··· 7.37 mg/l Glycine 4.85 mg/l Alanine 6.6 mg/l Citrulline 1.05mg/! Valine 11.13 mg/l Isoleucine 4.85mg/! Leucin 9.44 mg/l Tyrosine 3.26 mg/l Phenylalanine 4.95 mg/l ß-Alanine <0.27 mg/l ß-Aminoisobutyric acid - 1.03mg/! Ornithine 0.53 mg/l Lysine 7.99 mg/l Histidine 1.4 mg/l NATURAL GROWTH FACTORS IGF-1 (Somatomedin C) 70.0ng/ml IGF-2 not detectable TGF-ß not detectable

Example 3

The colostrum milk product according to Example 1 is prepared according to known

Process enclosed in liposomes and incorporated into a cream base {in the example case Soya oil, Tegomuls, vitamin E-I-A, cholesterol, HSA,. Contrex, carotene EJF ■+- HF, orange blossom oil, lemon balm oil, mandarin oil, Neroii oil and aqua dest. with a liposome content of 0.1 ml/g oil U0%H".

Such a liposome cream was used to investigate its effects on wound healing and on neurodermatitis eczema.

As already described at the beginning, a significant improvement in the overall dermatological appearance of neurodermatitis was shown in a placebo-controlled cross-over study, with 20 subjects participating in the test group and 15 subjects participating in the control group.

Thus, the present invention provides a product for the first time with which it is possible to convert the most important components of colostrum almost quantitatively into a colostrum product which then has high levels of growth factors and immunoglobulins.

Of course, it is possible to obtain targeted fractions, for example immunoglobulin-enriched fractions and/or growth factor fractions, which can then be administered separately, either orally, or enclosed in liposomes and then applied to the skin in the form of creams, pastes, ointments or emulsions.

Such a fractionation of the colostrum product according to the invention is achieved by further ultrafiltration with defined exclusion molecular masses of 300 kDa and/or 150 kDa and/or 100 kDa and/or 50 kDa and/or 30 kDa and/or 20 kDa and/or 10 kDa and/or 5 kDa and/or 1 kDa and/or 0.5 kDa.

Furthermore, it can be advantageous to raise the pH further before further fractionation, for example if desalination is carried out at 1 kDa or 0.5 kDa, in order to make the molecules large enough again so that they do not pass through the filter. Whether or not a pH increase should be carried out depends largely on what you want to achieve with further fractionation.

Which exclusion molecular mass the expert chooses also depends on which other fractions he would like to obtain from the colostrum product according to the invention.

Claims (16)

Michael Achenbach A 3829 - Cs/ho Protection claims 1. Colostrum milk product, characterized in that it is at least largely decaseinated and defatted crude colostrum is acidified such that casein remains in solution, and that the product is ultrafiltered with an exclusion molecular mass of approximately 10 ⁶ Da. 2. Colostrum milk product according to claim 1,
characterized in that the product is ultrafiltered and fractionated into different molecular mass ranges. 3. Colostrum milk product according to one of claims 1 or 2, characterized in that the pH value is adjusted to the pH value of the raw colostrum, in particular to a pH value of about 3.0 to 6.9, preferably about 4.0 to 5.5, particularly preferably to about 4.6. 4. Colostrum milk product according to one of the preceding claims, characterized in that the agent for acidifying and/or pH adjustment consists of Hydrochloric acid, phosphoric acid, lactic acid and/or citric acid. 5. Colostrum milk product according to one of the preceding claims, characterized in that it is desalted. 6. Colostrum milk product according to one of the preceding claims, characterized in that it is desugared. 7. Colostrum milk product according to one of the preceding claims, characterized in that additives, in particular vitamins, flavorings, flavor enhancers, preservatives, etc. are added. 8. Colostrum milk product according to one of the preceding claims, characterized in that it is sterilized, in particular sterile-filtered. 9. Colostrum milk product according to one of the preceding claims, characterized in that it contains at least about 75 ng/ml IGF-I. 10. Colostrum milk product according to one of the preceding claims, characterized in that it contains, based on the raw colostrum, about 50 to 95%, in particular about 60 to 95%, preferably 70 to 95 %, particularly preferably ·· preferably contains approximately 80 to 95%, particularly preferably at least approximately 90% of the growth factors present in the raw colostrum. 11. Colostrum milk product according to one of the preceding claims, characterized in that it is of bovine or equine origin. 12. Colostrum milk product according to one of the preceding claims, characterized in that it is in liquid, solid, pasty or microencapsulated form, in particular enclosed in liposomes. 13. Colostrum product according to one of the preceding claims, characterized in that it has the form of a beverage. 14. Colostrum milk product according to one of the preceding claims, characterized in that it is designed as a medicament, food supplement, beverage or cosmetic. 15. Colostrum milk product according to one of the preceding claims, characterized in that it is designed as an additive for medicines, food supplements, beverages or cosmetics. 16. Colostrum milk product according to one of the preceding claims, characterized in that it is added as a component to baby food, dietetic food, clinical food, in particular tube feeding.